Gonadotrophin-releasing hormone antagonists for assisted reproductive technology - Wikidata - awgldk - TriplyDB

Gonadotrophin-releasing hormone antagonists for assisted reproductive technology

Gonadotrophin-releasing hormone antagonists for assisted reproductive technology

http://www.wikidata.org/entity/Q24234608

about

Optimal usage of the GnRH antagonists: a review of the literature Gonadotrophin-releasing hormone antagonists for assisted reproductive technology Long-acting FSH versus daily FSH for women undergoing assisted reproduction Assisted reproductive technology: an overview of Cochrane Reviews Ovarian cyst aspiration prior to in vitro fertilization treatment for subfertility Assisted reproductive technology: an overview of Cochrane Reviews Assisted reproductive technology: an overview of Cochrane Reviews Natural cycle IVF for subfertile couples Long-acting FSH versus daily FSH for women undergoing assisted reproduction Long-acting FSH versus daily FSH for women undergoing assisted reproduction Ovarian hyperstimulation syndrome: pathophysiology, staging, prediction and prevention Subcutaneous Progesterone Is Effective and Safe for Luteal Phase Support in IVF: An Individual Patient Data Meta-Analysis of the Phase III Trials The German Middleway as Precursor for Single Embryo Transfer. A Retrospective Data-analysis of the Düsseldorf University Hospital's Interdisciplinary Fertility Centre - UniKiD.Evidence of GnRH antagonist escape in obese women.Comparisons of GnRH antagonist protocol versus GnRH agonist long protocol in patients with normal ovarian reserve: A systematic review and meta-analysis Comparison of gonadotropin-releasing hormone agonist with GnRH antagonist in polycystic ovary syndrome patients undergoing in vitro fertilization cycle: Retrospective analysis from a tertiary center and review of literature Pharmacokinetic, pharmacodynamic, and clinical aspects of ovulation induction agents: A review of the literature GnRH antagonist for patients with polycystic ovary syndrome undergoing controlled ovarian hyperstimulation for in vitro fertilization and embryo transfer in fresh cycles.The rate of high ovarian response in women identified at risk by a high serum AMH level is influenced by the type of gonadotropin Prognostic models for high and low ovarian responses in controlled ovarian stimulation using a GnRH antagonist protocol Management of poor responders in IVF: is there anything new?Comparisons of GnRH antagonist versus GnRH agonist protocol in supposed normal ovarian responders undergoing IVF: a systematic review and meta-analysis.Endometrial thickness affects the outcome of in vitro fertilization and embryo transfer in normal responders after GnRH antagonist administration.The physiology and clinical utility of anti-Mullerian hormone in women.Cetrotide administration in the early luteal phase in patients at high risk of ovarian hyperstimulation syndrome: A controlled clinical study.Dopamine agonists for preventing ovarian hyperstimulation syndrome.Outpatient management of severe early OHSS by administration of GnRH antagonist in the luteal phase: an observational cohort study Epidemiology, diagnosis, and management of polycystic ovary syndrome Scheduling cycles with gonadotropin-releasing hormone antagonist protocol in in vitro fertilization: Is there a scope in batch in vitro fertilization?The role of corifollitropin alfa in controlled ovarian stimulation for IVF in combination with GnRH antagonist.Comparison of GnRH agonist, GnRH antagonist, and GnRH antagonist mild protocol of controlled ovarian hyperstimulation in good prognosis patients Anti-müllerian hormone levels as a predictor of the pregnancy rate in women of advanced reproductive age.Estradiol Valerate Pretreatment in Short Protocol GnRH-Agonist Cycles versus Combined Pretreatment with Oral Contraceptive Pills in Long Protocol GnRH-Agonist Cycles: A Randomised Controlled Trial.Impact of different controlled ovarian stimulation protocols on the physical and psychological burdens in women undergoing in vitro fertilization/intra cytoplasmic sperm injection Is the GnRH Antagonist Protocol Effective at Preventing OHSS for Potentially High Responders Undergoing IVF/ICSI?E-selectin, resistin and reactive oxygen species levels in GnRH -agonist and -antagonist protocols in IVF/ICSI: a prospective cohort study.Fertility preservation in reproductive-age women facing gonadotoxic treatments.Ovarian hyperstimulation syndrome after gonadotropin-releasing hormone agonist triggering and "freeze-all": in-depth analysis of genetic predisposition.Prediction of ovarian hyperstimulation syndrome in coasted patients in an IVF/ICSI program.GnRH agonist versus GnRH antagonist in in vitro fertilization and embryo transfer (IVF/ET).

P2860

Q21245566-3B5A26D0-D594-4A18-BC7A-8B34A898FF5A Q24185849-12C996DB-D668-496A-84C1-EC1D8D270745 Q24186504-96C124EB-40B6-4F2B-8EF0-BAD1E2DF46B0 Q24186642-8BB0A074-CB96-4EDF-AABA-8694F98FED6C Q24187338-E2141A81-B69F-41BC-B612-ABDE707342F7 Q24187504-947FC8A7-84E2-4779-8001-6E9B0E4E2CDF Q24200639-F092BF84-9CE8-4B67-AC77-DFA753D84585 Q24202578-1795FDD8-2E6E-446C-AB46-20D0AD22B4CA Q24202586-1680A722-B3DD-4D99-B44B-4755FE247DD4 Q24203939-B59E69E8-6AA9-4F97-ABE7-B3AFB65A565E Q26827593-24020667-76E4-4F57-A6E7-2550D45350BD Q28550893-91F78469-E6DE-406C-9BBF-47BAB339487C Q31111724-7C54322D-BF68-486B-AAB5-96359D4C4101 Q33569055-C9890732-07FF-438B-A1AF-2DB9FED244DB Q33596777-AEFD440D-6440-4014-B7A3-18374520DF32 Q33601506-B4BB7283-623C-4E2A-8BDE-109A71548306 Q33743109-23304184-47AB-4A9A-8C7D-74ED8EE5C90D Q33744049-F65DD829-477A-4CED-B849-9D12380E01C2 Q33761614-0EFC1168-62AE-4BE1-AE65-DE9444475B2D Q33888265-02DEC122-DAB2-4164-AD4D-8DA67D23212D Q34022512-EDF48EDA-12E6-44FF-A5FA-E4C1D201CF03 Q34172380-602F31CA-C8D2-4295-A22C-6407AC60A41E Q34340408-BF39B1A1-2E5C-4C73-8E8F-D7F620A066C9 Q34398233-2D91F21A-5038-414E-9739-BA9E3148BFAB Q34443933-29DD825F-501D-456E-A2EA-20E3FA77F344 Q34546236-DAB13EE1-5E00-4BD7-A7F2-8F4A1812EB27 Q34641919-D4481DE1-502A-41F0-9352-5F14F18293CC Q34658641-572E4D93-4764-4967-8BC2-6DD7410AB437 Q34975523-5C861FFB-79EA-4BC1-8A5D-3ABFDF44C111 Q35186161-344FB258-7093-4408-8686-1305ED5EBA3E Q35238906-FEF95D71-2463-4BBA-B2A9-EE9E7401B1E6 Q35320672-02E6E634-8A2E-4D99-B4F3-6BA16E327ACE Q35438068-2DA2219E-9F3C-4302-98AE-5E4AF5138C1F Q35770012-5F92604D-E4CD-438E-B557-FF5D074D9C81 Q35808082-9C74FD39-997E-4886-8B15-92F5358AE32B Q35816202-5E91346F-DED0-44F9-9B60-5DB11F9E1E5C Q35934317-6E07DFA0-3397-4C6C-A4C6-0638747C9497 Q35938164-D5E53A9B-B4FB-41DB-AE6C-2D1EC0CC5E8B Q36133371-D80F17EA-247F-4DD9-A72C-983B0BA3A8CC Q36235804-1BF972E8-BE7B-4DC9-81BB-FFA0790CEE55

P2860

Gonadotrophin-releasing hormone antagonists for assisted reproductive technology

http://www.wikidata.org/entity/Q24234608

description

2011 nî lūn-bûn

@nan

2011 թուականի Մայիսին հրատարակուած գիտական յօդուած

@hyw

2011 թվականի մայիսին հրատարակված գիտական հոդված

@hy

2011年の論文

@ja

2011年論文

@yue

2011年論文

@zh-hant

2011年論文

@zh-hk

2011年論文

@zh-mo

2011年論文

@zh-tw

2011年论文

@wuu

name

Gonadotrophin-releasing hormone antagonists for assisted reproductive technology

@ast

Gonadotrophin-releasing hormone antagonists for assisted reproductive technology

@en

Gonadotrophin-releasing hormone antagonists for assisted reproductive technology

@en-gb

Gonadotrophin-releasing hormone antagonists for assisted reproductive technology

@nl

type

label

Gonadotrophin-releasing hormone antagonists for assisted reproductive technology

@ast

Gonadotrophin-releasing hormone antagonists for assisted reproductive technology

@en

Gonadotrophin-releasing hormone antagonists for assisted reproductive technology

@en-gb

Gonadotrophin-releasing hormone antagonists for assisted reproductive technology

@nl

prefLabel

Gonadotrophin-releasing hormone antagonists for assisted reproductive technology

@ast

Gonadotrophin-releasing hormone antagonists for assisted reproductive technology

@en

Gonadotrophin-releasing hormone antagonists for assisted reproductive technology

@en-gb

Gonadotrophin-releasing hormone antagonists for assisted reproductive technology

@nl

P1433

Q24234608-8E7ED5EF-628A-4EAC-9EB3-7AD3D5168EBC

P1476

Q24234608-BF959FAD-F06D-4D19-936D-958CF34232AC

P2093

Q24234608-01D65B81-2C8A-461E-92BC-83B40E04C975

Q24234608-0CE840A0-FE4D-49E5-8CDC-3245A7B4CE4E

Q24234608-4FD51C94-9B43-4D91-A507-94D63F96DE6D

Q24234608-62E82122-0895-4C78-9A88-282EC305029F

Q24234608-7429788D-4D25-47DF-8CD7-F66CFB37A5A5

Q24234608-B3A47B54-117A-454A-A667-2B938C4414EA

Q24234608-E4C1CAEF-FC18-4ECB-A79A-6FD18C8DAF4C

P2860

Q24234608-00D35BB0-731A-4498-8D8F-003E0F781DDA

Q24234608-050FC4C3-97F7-4D35-A8AC-02481010D652

Q24234608-0C9BEFA7-1188-4C90-8D93-85C21B1F9E78

Q24234608-1A31C43A-8505-4BA3-ABEB-38B0AEE6FD3B

Q24234608-2A80F045-1AC3-45C3-BF85-0AAA19FDF64A

Q24234608-2E989A38-CB97-42AE-85AF-8C61075162F1

Q24234608-303B6A3D-6288-4ACB-801A-968BECE1568D

Q24234608-344F3AB3-2D46-460C-99E9-085A3E0E1EB9

Q24234608-34523F51-4633-43F5-BB42-69AECCC8C971

Q24234608-3AD19A77-04C7-4E8B-9E1E-C5AFA0A6F26E

P31

Q24234608-C9189742-5469-4E0C-9806-451FBD29C180

Q24234608-e6bbcef2-a177-4eeb-a172-cba1374d5c04

P3181

Q24234608-3107A90B-21A3-419F-BAED-6D66F395289E

P356

Q24234608-A18670A6-A7D9-4FCD-9413-B1904C15BF94

P577

Q24234608-C03D87B2-7E1A-4435-A02D-F2AE35DD5FFB

P5875

Q24234608-97DC592F-DCB5-478E-B69C-F62DEC8349A2

P698

Q24234608-A43E20C5-BCCD-4981-A809-6029895179A7

P3181

P356

14651858.CD001750.PUB3

P1433

Cochrane Database of Systematic Reviews

P1476

Gonadotrophin-releasing hormone antagonists for assisted reproductive technology

@en

P2093

Ahmed M Abou-Setta

http://www.w3.org/2001/XMLSchema#string

Frank J Broekmans

http://www.w3.org/2001/XMLSchema#string

Hesham G Al-Inany

http://www.w3.org/2001/XMLSchema#string

Janine G Smit

http://www.w3.org/2001/XMLSchema#string

Mohamed AFM Youssef

http://www.w3.org/2001/XMLSchema#string

Mohamed Aboulghar

http://www.w3.org/2001/XMLSchema#string

Monique D. Sterrenburg

http://www.w3.org/2001/XMLSchema#string

P2860

Ovarian stimulation with HMG: results of a prospective randomized phase III European study comparing the luteinizing hormone-releasing hormone (LHRH)-antagonist cetrorelix and the LHRH-agonist buserelin. European Cetrorelix Study Group

Oral contraceptive pill, progestogen or estrogen pre-treatment for ovarian stimulation protocols for women undergoing assisted reproductive techniques

Gonadotrophin-releasing hormone antagonists for assisted conception

Does quality of reports of randomised trials affect estimates of intervention efficacy reported in meta-analyses?

Efficacy and safety of ganirelix acetate versus leuprolide acetate in women undergoing controlled ovarian hyperstimulation.

Gonadotropin releasing hormone agonist protocols for pituitary desensitization in in vitro fertilization and gamete intrafallopian transfer cycles.

The clinical therapeutic window for luteinizing hormone in controlled ovarian stimulation.

Association of inhibin B serum levels with parameters of follicular response in a randomized controlled trial comparing gnRH agonist versus antagonist protocols for ovarian hyperstimulation.

Among patients treated for IVF with gonadotrophins and GnRH analogues, is the probability of live birth dependent on the type of analogue used? A systematic review and meta-analysis.

Comparison of embryological and clinical outcome in GnRH antagonist vs. GnRH agonist protocols for in vitro fertilization in PCOS non-obese patients. A prospective randomized study.

P31

scholarly article

P3181

1941708

http://www.w3.org/2001/XMLSchema#string

P356

10.1002/14651858.CD001750.PUB3

http://www.w3.org/2001/XMLSchema#string

P577

2011-05-11T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

51118018

http://www.w3.org/2001/XMLSchema#string

P698

21563131

http://www.w3.org/2001/XMLSchema#string